Dr. Jianjun Gao, MD

Dr. Gao practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Gao's NPI, 1053356873, was assigned on June 17, 2006. Dr. Gao graduated from University of Kansas School of Medicine - Kansas City in 2006. Dr. Gao holds Texas license N9055.

Dr. Gao's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Gao's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gao practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Gao's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Gao is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Gao's licenses on file in 11 states: Texas, Florida, Georgia, Arizona, Louisiana, Oklahoma, Tennessee, Washington, Alabama, Mississippi and Wisconsin.

Dmand AI lists chronic leukemia, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Gao treats.

CMS data shows 213 Medicare services from Dr. Gao across 3 procedure codes in 2024, for 63 Medicare patients. Medicare paid $23,356 for them.

CMS counts 63 Medicare patients who saw Dr. Gao in 2024. The largest group is 65 to 74, with 29 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 3.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gao's median patient age at 75, with 24% women.

In 2024, Dr. Gao wrote 41 Medicare Part D claims for 12 patients. 88% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $75 in total drug cost. In 2021, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Gao for performance year 2024, reported as part of a group. Dr. Gao accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gao as offering telehealth.

Dmand AI links 87 papers to Dr. Gao, published from 2004 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Urinary Bladder Neoplasms, Kidney Neoplasms and Carcinoma, Renal Cell. Dr. Gao has published most often in Nat Commun. Dr. Gao's most frequent co-authors are Matthew T. Campbell, MD, Nizar M. Tannir, MD and Pavlos Msaouel, MD, PhD.

Dmand AI links Dr. Gao to 1 clinical trial. Conditions studied include Carcinoma, Transitional Cell and Carcinoma.

CMS Open Payments shows 149 general payments to Dr. Gao from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. AstraZeneca Pharmaceuticals LP paid the most, $33,527.

Dr. Gao graduated from University of Kansas School of Medicine - Kansas City in 2006. Dr. Gao is a member of ASCO.

Dr. Gao is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.